IceCure Medical enters its post-earnings week under dual pressure: a Q1 revenue miss and a fresh Nasdaq compliance notice have coincided with the sharpest short-selling build the stock has seen in months.
The catalyst is clear. IceCure reported Q1 2026 results on May 12, posting revenue of $911k against a $1.34M estimate — a miss of roughly 32%. EPS came in at -$0.06, worse than the -$0.05 consensus. The company simultaneously disclosed it received a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, a formal acknowledgment that the stock's prolonged sub-$1 trading has triggered exchange scrutiny. The price has dropped 16% on the week to $0.24, and is down 26% over the past month.
Short interest has accelerated sharply in response. SI as a percentage of free float has climbed to 3.2% — up 45% week-on-week and more than double the level from a month ago, when it was running near 1%. In absolute terms, shares short rose 12% in a single session on May 12. Despite that build, the borrow market remains far from stressed. Availability is running at roughly 304% of outstanding short interest, meaning lenders hold about three times as many shares as are currently borrowed. That has fallen steeply from above 600% earlier this month, as demand for borrows has picked up, but it is still well within comfortable territory. Cost to borrow has edged up just 2.5% on the week to 9.94% APR — elevated for a small-cap name, but essentially flat for the past month. The ORTEX short score has risen from 41.7 at the end of April to 53.1 now, a meaningful move but still in mid-range territory, not extreme.
The factor picture reinforces the cautious backdrop. ICCM's EPS surprise score ranks in the 84th percentile — historically the company has beaten estimates — making this quarter's miss notable by comparison. The short score rank sits at just the 21st percentile, meaning the market is not yet treating this as a heavily-shorted name in a broader context. Enterprise value is a thin $8.9 million, and all reported earnings multiples are negative, reflecting ongoing losses. No analyst coverage is visible in the data, so there is no Street consensus or target to weigh against the current price.
Ownership is heavily concentrated. Haixiang Li holds 44% of shares, a position that reportedly grew by 10 million shares as recently as March. The next largest named holders are officers and directors with sub-1% stakes. Institutional depth is minimal — Jane Street, UBS Asset Management, and Warberg Asset Management together account for less than 0.4% of shares. That concentration means the tradeable float is thin, which amplifies the effect of even modest short-selling demand on availability.
The prior earnings print from March 27 is worth noting: the stock fell 28% the following day and was still down 23% five days later. The next event date is flagged for May 27. Whether the pattern of sharp post-result moves repeats is the detail to track, alongside any further Nasdaq compliance updates and whether borrow availability continues to tighten as shorts remain in build mode.
See the live data behind this article on ORTEX.
Open ICCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
